Johnson & Johnson seeks FDA approval of Spravato as depression monotherapy
by
Contributor since / Followers
Contributor since / Followers
4 months ago
Sundry Photography/iStock Editorial via Getty Images
- Johnson & Johnson (NYSE:JNJ) announced the submission of a supplemental New Drug Application to the U.S. FDA seeking approval of Spravato nasal spray as a monotherapy for adults living with treatment-resistant depression.
- Spravato (esketamine) is approved by the FDA, in combination with an oral antidepressant, to treat adults with TRD and depressive symptoms in adults with major depression with acute suicidal ideation or behavior.
- Source: Press Release